Skip to main content

Table 1 Included studies and sample characteristics. Animal model, study groups, treatment start point and its duration, period of evaluation, implants specification, and evaluation methods

From: Systemic administration of strontium ranelate to enhance the osseointegration of implants: systematic review of animal studies

Study   Sample characteristics
Animal model Study groups Treatment start Duration of the treatment and period of examination Implant specification Evaluation methods
Maïmoun et al. 2010 [29] Female rats C: 0.5% carboxymethylcellulose aqueous solution (gavage, 5 days a week, n = 15)
SRAN: 625 mg/kg of strontium ranelate, for 8 weeks following implantation (gavage, 5 days a week, n = 15)
nd 8 weeks 1.0 × 4.1 mm pure titanium, with sand-blasted, acid-etched surface, inserted in the tibial methaphysis, bilaterally Microtomography, pull-out biomechanical test, and nanoindentation tests
Li et al. 2010 [32] Female rats CS: sham operation as a control group, and did not receive any drug treatments (n = 10)
OVX: bilateral ovariectomy 12 weeks before implantation (n = 10)
OVX + SRANL: bilateral ovariectomy 12 weeks before implantation, plus special diet providing 500 mg/kg/day of strontium ranelate after implantation (n = 10)
OVX + SRANH: bilateral ovariectomy 12 weeks before implantation, plus special diet providing 1000 mg/kg/day of strontium ranelate after implantation (n = 10)
Started on the day of implantation 12 weeks 1.8 × 3.5 mm, sand-blasted and with sprayed HA-coating, inserted in the tibiae, unilaterally Microtomography, push-out biomechanical test
Li et al. 2012 [33] Female rats OVX: bilateral ovariectomy, 12 weeks before implantation (n = 10)
OVX + SRAN: bilateral ovariectomy 12 weeks before implantation, plus special diet providing 625 mg/kg/day of strontium ranelate after implantation (n = 10)
Started on the day of implantation 12 weeks 1.2 × 10.0 mm commercially pure titanium, machined and grit-blasted with aluminum oxide, inserted in the distal femur, bilaterally Microtomography, histomorphometric (BA and BIC), serum analysis (OCN and TRAP), and push-out biomechanical test
Linderbäck et al. 2012 [30] Male rats C: normal diet (n = 20)
BPA: 20 μg/kg/day subcutaneous alendronate, three times a week (n = 20)
SRAN: special diet containing 800 mg/kg/day strontium ranelate (n = 20)
BPA group started within 24 h after implantation
SR group started on the day of implantation
4 and 8 weeks 1.6 × 2.5 mm stainless steel and polymethyl methacrylate (PMMA) screws, inserted in the tibial methaphysis, bilaterally Microtomography, pull-out biomechanical test, histomorphometric analysis (BA), and bone mineral analyses (ash weight)
Chen et al. 2013 [31] Female rats CS: sham operation as a control group, and did not receive any drug treatments (n = 12)
OVX: bilateral ovariectomy 4 weeks before implantation, and did not receive any drug treatments (n = 11)
OVX+BPA: bilateral ovariectomy 4 weeks before implantation, alendronate 7 mg/kg/week orally (n = 10)
OVX+SRAN: bilateral ovariectomy 4 weeks before implantation, strontium ranelate 500 mg/kg/day orally (n = 12)
OVX+BPZ: bilateral ovariectomy 4 weeks before implantation, single dose of zoledronic acid 0.1 mg/kg intravenous (n = 11)
1 week after implantation 11 and 12 weeks 1.0 × 10.0 mm titanium plasma-sprayed with hydroxyapatite, inserted in the tibial methaphysis, bilaterally Bone mineral density, histological analysis, and push-out biomechanical test
  1. C S sham operation as a control positive group, C control, SRAN strontium ranelate, OVX ovariectomy, SRAN L strontium ranelate low dose, SRANH strontium ranelate high dose, BP bisphosphonate, BP A alendronate, BP Z zolendronate, nd non declared